179 related articles for article (PubMed ID: 27213173)
1. Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS.
Thomas K; Eisele J; Rodriguez-Leal FA; Hainke U; Ziemssen T
Neurol Neuroimmunol Neuroinflamm; 2016 Jun; 3(3):e228. PubMed ID: 27213173
[TBL] [Abstract][Full Text] [Related]
2. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab infusion-associated reactions and laboratory changes in patients with relapsing-remitting multiple sclerosis at baseline and first-year follow-up.
Saridas F; Mercan Saridas F; Koc ER; Turan OF
Heliyon; 2024 Mar; 10(5):e26900. PubMed ID: 38444472
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
7. Effect of Alemtuzumab Infusions on Vital Signs: A Prospective Observational Study in Patients with Relapsing-Remitting Multiple Sclerosis.
Chinea A; Honeycutt WD; Miller T; Graves D; Jacobs A; Wu J; LaGanke CC
Int J MS Care; 2020; 22(2):53-59. PubMed ID: 32410899
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Perumal JS; Foo F; Cook P; Khan O
Mult Scler; 2012 Aug; 18(8):1197-9. PubMed ID: 22252465
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
[TBL] [Abstract][Full Text] [Related]
10. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
11. Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon.
Puthenparampil M; Rinaldi F; Federle L; Cazzola C; Perini P; Gallo P
Ther Adv Neurol Disord; 2018; 11():1756285617741056. PubMed ID: 29399047
[TBL] [Abstract][Full Text] [Related]
12. Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses.
Anderson AE; Lorenzi AR; Pratt A; Wooldridge T; Diboll J; Hilkens CM; Isaacs JD
Rheumatology (Oxford); 2012 Aug; 51(8):1397-406. PubMed ID: 22447884
[TBL] [Abstract][Full Text] [Related]
13. Current evaluation of alemtuzumab in multiple sclerosis.
Coyle PK
Expert Opin Biol Ther; 2014 Jan; 14(1):127-35. PubMed ID: 24289293
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Cossburn MD; Harding K; Ingram G; El-Shanawany T; Heaps A; Pickersgill TP; Jolles S; Robertson NP
Neurology; 2013 Jan; 80(1):55-61. PubMed ID: 23243077
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab in multiple sclerosis: an update.
Gross RH; Krieger S
Neurodegener Dis Manag; 2015; 5(3):225-32. PubMed ID: 26107321
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab treatment of multiple sclerosis.
Coles AJ
Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Skoromets A; Stolyarov I; Bass A; Sullivan H; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Neurology; 2012 Apr; 78(14):1069-78. PubMed ID: 22442431
[TBL] [Abstract][Full Text] [Related]
18. Definition of the variables affecting efficacy of immunodepletion ex vivo of peripheral blood progenitor cell grafts by alemtuzumab (Campath in the bag).
Novitzky N; Davison G; Abdulla R; Mowla S
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1753-9. PubMed ID: 24120379
[TBL] [Abstract][Full Text] [Related]
19. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
Fox EJ; Sullivan HC; Gazda SK; Mayer L; O'Donnell L; Melia K; Lake SL
Eur J Neurol; 2012 Feb; 19(2):307-11. PubMed ID: 21899662
[TBL] [Abstract][Full Text] [Related]
20. The outlook for alemtuzumab in multiple sclerosis.
Williams T; Coles A; Azzopardi L
BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]